Skip to main content
I.Ceram logo

I.Ceram — Investor Relations & Filings

Ticker · ALICR ISIN · FR0011511971 LEI · 969500R28RHD3HDEIL86 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2017-06-06 Capital/Financing Update
Country FR France
Listing PA ALICR

About I.Ceram

https://www.iceram.fr/

I.Ceram specializes in the design, manufacture, and marketing of orthopedic and reconstructive implants. The company's core technology is centered on porous alumina bioceramics, though it also utilizes metals and polymers. A key innovation is the development of active implants, such as its Ceramil line, which can be loaded with antibiotics like gentamicin. This feature enables the localized delivery of medication directly to bone tissue to prevent and treat infections post-surgery. The product portfolio includes implants for various joints and a bioceramic sternal implant designed for reconstructive procedures.

Recent filings

Filing Released Lang Actions
Eligibilité d’I.CERAM au dispositif PEA-PME 2017
Capital/Financing Update Classification · 1% confidence The document is very short (1542 characters) and announces that the company I.Ceram is eligible for the PEA-PME investment scheme, citing relevant French financial decrees. It also provides general company information, contact details, and mentions its stock market listing (Alternext Euronext Paris). This type of announcement, which confirms eligibility for specific financial/tax regimes or provides general corporate updates without being a full financial report (like 10-K or IR) or a specific transaction report (like DIV or DIRS), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory/corporate update, or potentially 'Capital/Financing Update' (CAP) due to the mention of investment schemes. Given the focus is on regulatory eligibility confirmation rather than a specific financing event or dividend, RNS is the most appropriate fallback for a short, specific regulatory confirmation.
2017-06-06 French
Mise à disposition du Document de référence 2016
Report Publication Announcement Classification · 1% confidence The document is titled "Mise à disposition du Document de Référence 2016" (Making available of the 2016 Reference Document). It explicitly states that the company (I.CERAM) has obtained registration from the AMF (Autorité des Marchés Financiers) for its 2016 Reference Document, which includes the 2016 annual financial report and management report. Crucially, the text focuses on *where* this document can be consulted and downloaded, rather than containing the full content of the annual report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is available points towards a Report Publication Announcement (RPA). While the content relates to an Annual Report (10-K), the document's function here is to announce its availability.
2017-04-27 French
Renforcement du Comité Scientifique d’I.CERAM et Obtention du marquage CE en cours
Board/Management Information Classification · 1% confidence The document announces two main pieces of news: the addition of two medical professionals to the Scientific Committee and the confirmation that the CE marking process for their sternum implant is underway but delayed due to administrative reasons related to notified bodies. The content focuses on scientific/R&D reinforcement and regulatory progress updates, rather than a full financial report (10-K, IR), a specific transaction (DIV, POS), or a general earnings release (ER). The announcement of management/board changes (MANG) is related to the Scientific Committee, which is a governance/advisory body, but the core theme is scientific development and regulatory status. Since it is an announcement detailing changes in key personnel related to R&D and providing an update on a critical regulatory milestone (CE marking), it aligns best with general corporate information updates. Given the options, this is a significant corporate announcement that doesn't fit perfectly into the financial reporting categories. However, the appointment of key scientific advisors and the update on regulatory progress are often grouped with management/governance updates or general regulatory news. Since it details changes in key personnel (scientific committee members) and provides an update on a regulatory process, it is closest to Board/Management Information (MANG) or a general Regulatory Filing (RNS). Because it explicitly details the joining of new members to a committee, MANG is a strong candidate, although the regulatory update is also prominent. Given the focus on personnel joining a high-level advisory board, MANG is selected over the general RNS fallback.
2017-04-18 French
Signature d’un contrat de collaboration stratégique avec l’Université Paris 13
Regulatory Filings Classification · 1% confidence The document announces a strategic collaboration agreement signed between I.CERAM and Université Paris 13 concerning R&D for orthopedic implants. This type of announcement, detailing a partnership, strategic development, or specific corporate action that isn't a standard financial report (like 10-K, ER, or IR), typically falls under general corporate news or regulatory updates. Since it is not a formal financial filing (like 10-K, IR, ER), nor a management change (MANG), nor a financing event (CAP), nor a director dealing (DIRS), the most appropriate category is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it communicates a significant, non-financial operational event to the market. The document length (4010 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication (RPA).
2017-04-05 French
La clinique Saint-George de Nice implante son 1er sternum CERAMIL®
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific medical procedure milestone (the first implantation of a CERAMIL® sternum at a specific clinic) and its implication for the company's ongoing clinical research (protocol STOIC) and future CE marking. It is not a formal regulatory filing like a 10-K, IR, or ER. It details company progress, technology, and future commercialization goals, which aligns best with a general corporate announcement or news release. Since there is no specific category for 'Press Release' or 'Company News', and it is not a formal financial report, a management update, or a capital event, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it serves as a general corporate disclosure that doesn't fit the highly specific financial/governance categories provided.
2017-03-13 French
ICERAM : Descriptif Programme Rachat d'Actions
Transaction in Own Shares Classification · 1% confidence The document explicitly describes the objectives and modalities of a share repurchase program authorized by the Shareholders' General Meeting (Assemblée Générale Mixte) on June 30, 2016. It details the number of shares held, the breakdown by objective (e.g., covering securities, liquidity provision, cancellation), the maximum acquisition price (€17), the total authorized amount (€800,000), and the duration (18 months). This content directly relates to the company's actions regarding its own shares, which aligns perfectly with the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA), but the detailed description of the buyback plan itself.
2017-03-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.